About Betaserc

The information below should not be taken as a substitute for qualified medical advice. Consult your health care provider before taking Betaserc.

Betaserc is prescribed to treat the dizziness, vertigo, hearing loss, and tinnitus reported by those with M�ni�re's Disease. It is also prescribed for those with other balance disorders. This medication, a histamine antagonist, dilates blood vessels in the middle ear, relieving internal pressure from excess fluids, and reducing the severity of light-headedness or vertigo.

Symptom improvement can be noticed as early as two weeks after beginning treatment, but the best results can take up to three months.

Betaserc should be taken as directed by a health care provider. If a dose is missed, it should be taken as soon as it is remembered unless this might cause a "doubling up" of the dose. In this case, the dose should be skipped in favor of resuming the regular dosing regimen.

Betaserc is known to suppress appetite as a side effect, and as such has recently undergone trials as a treatment for obesity. Women under the age of fifty who took this medication for twelve weeks lost up to seven times the weight of those who took a placebo, all without serious side effects. The women averaged a weight loss of 2.91% of their body mass, compared to the 0.4% loss by the placebo group.

The drug is also undergoing a pilot study as a possible treatment for certain types of atypical depression, though at relatively high doses. It's thought that Betaserc's properties as a histamine antagonist will act to increase bioavailability of dopamine and serotonin in the nervous system.

The side effects related to Betaserc are mild and uncommon, but include headaches, gastric upsets, nausea, or decreased appetite.

Betaserc is not commercially available in the United States, Canada, or Great Britain. Its current availability is restricted to Austria, Bahrain, Bangladesh, Belgium, Brazil, Bulgaria, Colombia, Croatia, the Czech Republic, Denmark, Estonia, Finland, France, Georgia, Greece, Hong Kong, Hungary, Iceland, Indonesia, Latvia, Lithuania, Luxembourg, Malaysia, Malta, Myanmar, the Netherlands, Oman, Peru, Poland, Portugal, Romania, Russia, Singapore, Slovakia, Slovenia, Sri Lanka, Tunisia, Turkey, Taiwan, and Vietnam.